Key result
In a real-world Chinese population of 1,800 all-comers, implantation with the Resolute drug-eluting stent demonstrated a 5-year target lesion failure rate of 9.8%.
Why the study?
Long-term clinical outcome data for second-generation drug-eluting stents are critical to assess their safety and efficacy.
Does the Resolute drug-eluting stent provide safe and effective long-term outcomes in an all-comers Chinese population requiring percutaneous coronary intervention?
Observational (n=1,800)
Yes
Does the Resolute drug-eluting stent provide safe and effective long-term outcomes in an all-comers Chinese population requiring percutaneous coronary intervention?
The Resolute drug-eluting stent demonstrated a robust long-term safety and efficacy profile at 5 years in a real-world, all-comers Chinese population, with low rates of target lesion failure and stent thrombosis.
Supports durable safety of second-generation DES in all-comers; extends real-world data but leaves open need for randomized confirmation.
AIMS: Long-term clinical outcome data for second-generation drug-eluting stents (DES) are critical for the assessment of safety and efficacy. Five-year results from the RESOLUTE China Registry are presented in this report. METHODS AND RESULTS: The RESOLUTE China Registry is a prospective, multicentre, observational study for all-comers requiring coronary stent implantation. The primary endpoint was target lesion failure (TLF) at one year, and the main secondary endpoint was definite or probable stent thrombosis at one year. Additional secondary endpoints assessed up to 5 years include rates of all deaths, target vessel myocardial infarction (TVMI) and target lesion revascularisation (TLR). A total of 1,800 patients were enrolled from December 2010 to March 2012 at 30 sites in China and implanted with Resolute DES. At 5 years, TLF was 9.8%, TVMI 3.2%, TLR 4.6% and very late stent thrombosis 0.5%. Results of pre-specified subgroup analyses show 5-year TLF rates of 14.3% for diabetics and 13.4% for patients with chronic total occlusions. CONCLUSIONS: The RESOLUTE China Registry is the largest study of Asian patients treated with second-generation Resolute DES. Clinical outcomes illustrate a robust safety and efficacy profile of Resolute DES in a real-word Asian population, including favourable performance in complex patient subsets.
No takes yet. Share an insight, caveat, or question.
Qiao et al. (2021) conducted an observational in Coronary artery disease requiring percutaneous coronary intervention (n=1,800). Resolute drug-eluting stent was evaluated on Target lesion failure (TLF) at 5 years. In a real-world Chinese population of 1,800 all-comers, implantation with the Resolute drug-eluting stent demonstrated a 5-year target lesion failure rate of 9.8%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: